Tasigna (nilotinib) is a prescription medication used to treat chronic myelogenous leukemia (CML), a type of blood cancer. Tasigna is manufactured by Novartis.
Lawsuits
Several lawsuits have been filed against Novartis alleging that Tasigna caused serious side effects, including:
- Atherosclerosis, a hardening of the arteries that can lead to heart attacks, strokes, and other cardiovascular problems
- Peripheral arterial disease (PAD), a narrowing of the arteries in the legs and feet
- Limb amputation
- Death
Allegations
The plaintiffs in the lawsuits allege that Novartis failed to adequately warn about the potential side effects of Tasigna and that the company’s marketing of the drug was misleading.
Status of the Lawsuits
The lawsuits are still ongoing. Novartis has denied the allegations and has stated that Tasigna is safe and effective.
Potential Impact of the Lawsuits
The lawsuits could have a significant impact on Novartis, including:
- Financial penalties
- Damage payments to plaintiffs
- Changes to the marketing and labeling of Tasigna
- A decline in sales of Tasigna
Recommendations for Consumers
Consumers should be aware of the potential side effects of Tasigna and should talk to their doctor about whether the drug is right for them.
Disclaimer
This information is not intended to be legal advice. You should always consult with an attorney to discuss your specific case.
